PROSTATE CANCER PATHWAY - Aviva Systems...
Click here to load reader
Transcript of PROSTATE CANCER PATHWAY - Aviva Systems...
PROSTATE CANCER PATHWAY
Aviva Product
Not a Aviva Product
Indirect effect
Another molecule, mostly chemical compound
InhibitionDissociationPhosphorylation+pDephosphorylation-p
Nucleus
Outside
Normal prostate epithelium
Testosterone
PIP3
-p
+p+p+p+p+p+p+p
+p
+p +p
+p
+p+p
+p+p
?
Tumor growth
Other target events
DNA DNA DNA
Impaired G1 and G2 arrestReduced apoptosisGenomic instability
Genomicdamage
Hypermethylation
Cell cycleprogression
Apoptosis inhibition
Cell proliferation
Survival
Dihydrote-stosterone
Otherligands
Proliferative inflammatory atrophy
Prostatic intraepithelial neoplasia
Localized prostate cancer
Metastatic prostate cancer
(Therapeutic decreasedtestosterone and
dilydrotestosterone)
Androgen-independentcancer
Pathway diagram below is compiled from data from the Kyote Encylopedia of Genes and GenomesKanehisa, M., Goto, S., Furumichi, M., Tanabe, M., and Hirakawa, M.; KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355-D360 (2010). Kanehisa, M., Goto, S., Hattori, M., Aoki-Kinoshita, K.F., Itoh, M., Kawashima, S., Katayama, T., Araki, M., and Hirakawa, M.; From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res. 34, D354-357 (2006). Kanehisa, M. and Goto, S.; KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27-30 (2000). © 2011 Aviva Systems Biology
Androgen and estrogen metabolism
SRD5A2
Carcinogens
Prostatic epithelial cell
Genetic alterationsOncogenes: ARTumor supressors:CDKN1B, NKX3.1, PTEN
Cell proliferation
Cell survival DNA
G1/S progression
DNA DNA DNA
Apoptosis
Cell Cycle
Cell Cycle
p53 signalingpathway
MAPK signalingpathway
Cytokine-cytokinereceptor interaction
CBP
TCF/LEF P53
CDK2
p27
E2F Rb
GSTP1
MDM2GSK3IKK
GF
Ras
Raf
MEKERK
AR
ARAR
SOS Grb2 PI3K
PTEN
PDK1
Casp9BADFKHR
IkBNFkB
CREBβ-Catenin
mTOR
NKX3.1
GFR
PKB/Akt
PSA BCL2 CyclinD1
p21p27
CyclinE
HSP